Pulmonary alveolar proteinosis (PAP)
Also known as: Alveolar proteinosis
Methodology & AI Transparency ⓘ
Pulmonary alveolar proteinosis (PAP) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Pulmonary alveolar proteinosis (PAP) (also termed Alveolar proteinosis) is an ICD-10-CM indexed diagnosis (J84.01) within Asthma, COPD & Respiratory Disease.
- 2 Real-world patient consensus: Synonyms for Pulmonary alveolar proteinosis (PAP) (J84.01): Alveolar proteinosis (Lungs & Asthma).
- 3 Typical cash cost range: Workup highlights for Pulmonary alveolar proteinosis (PAP) (J84.01): high-resolution chest imaging in Pulmonary alveolar proteinosis (PAP) (J84.01: when indicated).
- 4 Top reported side effects / signs: Follow-up benchmark in Pulmonary alveolar proteinosis (PAP): maintaining Spirometry FEV1 / in Pulmonary alveolar proteinosis (PAP) (J84.01: FVC Ratio) within >= 0.75 (FEV1 >= 80% predicted) (J84.01).
Ask our AI Specialists anything about Pulmonary alveolar proteinosis (PAP)
What Is Pulmonary alveolar proteinosis (PAP)?
Pulmonary alveolar proteinosis (PAP) (also termed Alveolar proteinosis) is an ICD-10-CM indexed diagnosis (J84.01) within Asthma, COPD & Respiratory Disease. Clinical evaluation centers on high-resolution chest imaging in Pulmonary alveolar proteinosis (PAP) (J84.01: when indicated) alongside serial Spirometry FEV1 / in Pulmonary alveolar proteinosis (PAP) (J84.01: FVC Ratio) tracking (>= 0.75 (FEV1 >= 80% predicted) (J84.01)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Pulmonary alveolar proteinosis (PAP) (code J84.01) is eosinophilic or neutrophilic in Pulmonary alveolar proteinosis (PAP) (J84.01: airway mucosal inflammation), which Asthma, COPD & Respiratory Disease clinicians address while surveilling Spirometry FEV1 / in Pulmonary alveolar proteinosis (PAP) (J84.01: FVC Ratio) (>= 0.75 (FEV1 >= 80% predicted) (J84.01)).
Common Symptoms & Clinical Signs
- • Presentation of Pulmonary alveolar proteinosis (PAP) (J84.01): episodic wheezing, expiratory in Pulmonary alveolar proteinosis (PAP) (J84.01: chest tightness, or)
- • Secondary Pulmonary alveolar proteinosis (PAP) clinical sign: chronic productive or in Pulmonary alveolar proteinosis (PAP) (J84.01: dry cough worsening)
- • Symptom flares in Pulmonary alveolar proteinosis (PAP) correlating with Spirometry FEV1 / in Pulmonary alveolar proteinosis (PAP) (J84.01: FVC Ratio) deviation outside >= 0.75 (FEV1 >= 80% predicted) (J84.01)
- • Functional lungs & asthma impact requiring high-resolution chest imaging in Pulmonary alveolar proteinosis (PAP) (J84.01: when indicated) evaluation (J84.01)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Pulmonary alveolar proteinosis (PAP) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | J84.01 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Asthma, COPD & Respiratory Disease | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Spirometry FEV1 / in Pulmonary alveolar proteinosis (PAP) (J84.01: FVC Ratio) | >= 0.75 (FEV1 >= 80% predicted) (J84.01) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fractional Exhaled Nitric in Pulmonary alveolar proteinosis (PAP) (J84.01: Oxide (FeNO)) | < 25 ppb (J84.01) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Resting Pulse Oximetry in Pulmonary alveolar proteinosis (PAP) (J84.01: (SpO2)) | 96% – 100% (J84.01) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Pulmonary alveolar proteinosis (PAP)
Treatment selection for Pulmonary alveolar proteinosis (PAP) depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pulmonary alveolar proteinosis (PAP))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Sildenafil for congenital heart diseases induced lung high blood pressure, a: What a 849-Participant Study Found Sildenafil is a well-tolerated treatment in congenital heart diseases induced lung high blood pressure, as it has proven its efficacy not only in lowering both PAP mean and systolic but also in reducing the ventilation time,... BMC pediatrics • 2023-07-20 • Meta-Analysis | N = 849 | 97/100 | PMID 37474896 ↗ |
| New Insights on Relationship Between Time From Diagnosis and Morbidity/Mortality in lung Arterial: What a 1,156-Participant Study Found In the GRIPHON study, newly diagnosed PAH patients had a worse prognosis than patients with a longer time from diagnosis. Chest • 2021-07-15 • Phase III Randomized Trial | N = 1,156 | 96/100 | PMID 33545163 ↗ |
| New Insights on Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic: What a 975-Participant Study Found Ensifentrine produced clinically meaningful improvements in multiple dyspnea measures in patients with symptomatic, moderate-to-severe COPD. Expert review of respiratory medicine • 2024-08-15 • Phase III Randomized Trial | N = 975 | 93/100 | PMID 39106052 ↗ |
| What the Latest Evidence Really Says About Vasodilators for persistent lung high blood pressure of the newborn: A network Milrinone, Sildenafil, and Sildenafil_Milrinone reduced the mortality of neonates with PPHN. Pediatric pulmonology • 2024-12-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 39193897 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of melatonin administration on subjective sleep quality in chronic We conclude that melatonin can improve sleep in COPD. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas • 2008-10-15 • Randomized Controlled Trial | N = 12 | 88/100 | PMID 19030713 ↗ |
Pulmonary alveolar proteinosis (PAP) Patient Community & “People Like Me” Threads
Filter Pulmonary alveolar proteinosis (PAP) community threads and patient logs by age, biological sex, dosage, and treatment duration.